By Trae Carroll, Associate Pharmaceutical Scientist
Part 2 of a 2 part series
Microparticle encapsulated drugs are increasingly desirable dosage forms as clinicians seek to target specific sites in the body for controlled release therapy. In the previous blog post, we addressed the challenge of successfully formulating such compounds for oral administration. However, once you have successfully encapsulated an active pharmaceutical ingredient (API), the next task is to characterize that product and understand its release kinetics, such that it can be labeled and prepared for subsequent studies.